Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 93 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Aldara Clear all
Terminated Phase 1 Interventional

Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

NCT02689726
View directory record Official record
Conditions
HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL
Interventions
GTL001+, Aldara
Drug
Lead sponsor
Genticel
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Louisville, Kentucky • Raleigh, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin

NCT00453050
View directory record Official record
Conditions
Melanoma (Skin), Metastatic Cancer
Interventions
imiquimod, indocyanine green solution, flow cytometry, immunologic technique, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 21, 2026, 5:45 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV

NCT01663558
View directory record Official record
Conditions
Anal Dysplasia, Human Papilloma Virus, HIV
Interventions
imiquimod, ablative
Drug · Procedure
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 With or Without Topical Aldara in Healthy Adults

NCT03472976
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
Aqueous Cream B.P., Imiquimod, Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04
Other · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05375903
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
Interventions
UGN-301, UGN-201, Gemcitabine
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Results available

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

NCT00988559
View directory record Official record
Conditions
HPV16 Positive, Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions
DNA vaccination, Gene gun vaccine, intramuscular vaccination, intra-lesional vaccine administration, therapeutic resection of the lesion, imiquimod
Biological · Device · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 21, 2026, 5:45 AM EDT
Withdrawn Not applicable Interventional

Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses

NCT00814528
View directory record Official record
Conditions
Actinic Keratosis
Interventions
5-ALA plus Blu-Light, 5-FU, Imiquimod or treatment with cryotherapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 21, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional Results available

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

NCT00799110
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
GM-CSF, Dendritic Cell/Tumor Fusion Vaccine, imiquimod
Drug · Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Basal Cell Carcinoma Chemoprevention Trial

NCT05212246
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
5% Imiquimod cream, Placebo Vehicle Control Cream
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
8
States / cities
Long Beach, California • San Diego, California • Bay Pines, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Not listed Early Phase 1 Interventional

CTCL Directed Therapy

NCT03116659
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous
Interventions
Doxycycline, Imiquimod
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
30 Years to 89 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

NCT01264731
View directory record Official record
Conditions
Melanoma
Interventions
MELITAC 12.1, Imiquimod
Biological · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Results available

Bioequivalence Study of Two Imiquimod Cream 5%

NCT00828568
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod 5% manufactured by Taro, Aldara - Imiquimod 5%, Imiquimod Vehicle manufactured by Taro
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Gilbert, Arizona • Tempe, Arizona • Tuscon, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence

NCT00129519
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Imiquimod 5% cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Grass Valley, California • Loma Linda, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2010 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

NCT01593124
View directory record Official record
Conditions
Vaginal Inflammation, Vaginal Infections
Interventions
Imiquimod, Placebo, Nonoxynol-9
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis

NCT01686152
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product
Drug · Other
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Tucson, Arizona • Encino, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 21, 2026, 5:45 AM EDT
Active, not recruiting Phase 1 Interventional

A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630

NCT05055050
View directory record Official record
Conditions
Bladder Cancer, Bladder
Interventions
UGN-201
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)

NCT00605176
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod cream, Placebo
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Fremont, California • Los Angeles, California • Riverside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Oct 21, 2026, 5:45 AM EDT
Not listed Phase 4 Interventional

Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis

NCT01413763
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod cream 3.75%, Placebo cream
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Fort Meyers, Florida
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 4 Interventional

Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

NCT00581425
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Imiquimod and Interferon alpha
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

NCT00735462
View directory record Official record
Conditions
Genital Warts
Interventions
2.5% imiquimod cream, 3.75% imiquimod cream, Placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Jonesboro, Arkansas • Carmichael, California • Chico, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix

NCT02130323
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
Imiquimod, Loop Electrosurgical Excision Procedure
Drug · Procedure
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
21 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT00801320
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Tumor collection
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage

NCT00314756
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
imiquimod
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 21, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal

NCT00638651
View directory record Official record
Conditions
Healthy
Interventions
1064 nm Nd:YAG laser, Imiquimod, 5% cream
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 21, 2026, 5:45 AM EDT